Ziv-Aflibercept
Uterine Carcinosarcoma
National Cancer Institute (NCI)Phase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Uterine Carcinosarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin GOG Foundation | Phase 3 | B |
Ifosfamide GOG Foundation | Phase 3 | B |
Dostarlimab ARCAGY/ GINECO GROUP | Phase 2/3 | B |
Sorafenib National Cancer Institute (NCI) | Phase 2 | B |
Temsirolimus National Cancer Institute (NCI) | Phase 2 | B |
View all 14 →
Same molecule, other indications
Ziv-Aflibercept is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →